n = number of struts analyzed
ACS – Acute Coronary Syndrome; STEMI – ST-Elevation Myocardial Infarction; DM – Diabetes Mellitus. HBR – High Bleeding Risk; B2C – Complex Lesions; SV – Small Vessels; MVD – Multi-Vessel Disease

^a ø 2.25 – 3.0 mm; ^b Images: Secco G et al. Time-related changes in neointimal tissue coverage following a new generation SES implantation: an OCT observational study. Presented at: euro PCR, May 20, 2014; Paris, France; ^c Based on 1-year TLF SUCRA score, in comparison to Xience, Resolute and Nobori/BioMatrix, after a median follow-up period of 50 months; ^d Resolute Integrity and Resolute Onyx; ^e In comparison to Xience, based on statistically significant lower TV-MI and late/very late definite/probable ST rates from the BIOFLOW-V trial through 5 years; ^f p-values for 60-month frequentist analysis; ^g In comparison to Xience, based on BIOFLOW-V 5-year results; ^h As per IFU;  ⁱ Based on TLF primary endpoint, Iglesias J.F., BIOSTEMI 5 year follow up, Presented at TCT 2023, San Francisco USA Clinical data collected with the Orsiro DES device within the Orsiro family clinical program;  ^j BCI: Bayesian Credibility Interval; ^k n= 1,300 newly enrolled STEMI patients including 407 patients from the BIOSCIENCE STEMI subgroup used as prior information; ^l At 5-year in STEMI patients.  Based on TLF with Orsiro DES in comparison to Xience DES in STEMI patient; ^m In comparison to Resolute Integrity, based on 5-year results of the BIO-Resort trial SV subgroup.

1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. Per investigators’ interpretation of preclinical studies with Orsiro as mentioned in Cassese et al. J Thorac Dis 2018;10(2):688-692; 3. BIOTRONIK data on file; 4. Evaluation of Market Acceptance, BIOTRONIK data on file; 5. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis; 6. Secco G et al. Time-related changes in neointimal tissue coverage of a novel Sirolimus eluting stent: Serial observations with optical coherence tomography. Cardiovascular Revascularization Medicine 17.1 (2016): 38-43; 7. Stefanini GG et al. Coronary stents: novel developments. Heart. 2014 Jul 1;100(13):1051-61; 8. Low AF. Stent platform for procedural success: Introducing the Continuous Sinusoidal & Core Wire Technologies. Presented at: AsiaPCR; 22-24 January, 2015; Singapore, Singapore; 9. Tolentino A. Evolving DES Strategy: Biodegradable Polymer vs. Bioabsorbable Scaffold. Presented at: Cardiovascular Nurse/Technologist Symposium; June 17, 2016; New York, USA; 10. Based on investigator’s interpretation of BIOFLOW-V primary endpoint result; 11.Based on Taglieri et al. Meta-analysis, against currently used DES; 12. BIOTRONIK data on file, as of February 2023; 13. Taglieri N et al. Target lesion failure with current drug-eluting stents: Evidence from a comprehensive network meta-analysis. JACC 2020 13(24):2868-78; 14. Kandzari D et al. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents for Coronary Revascularization: Final 5-year Outcomes from the Randomized BIOFLOW V Trial, JACC, 2022: NCT02389946; 15. Iglesias J.F., BIOSTEMI 5 year follow up, Presented at TCT 2023, San Francisco USA. 16. Ploumen etal. BIO-RESORT Small Vessels 5Y-EuroPCR2022.

Clinical data collected with the Orsiro DES and/or Orsiro Mission DES device within the Orsiro family clinical program

Orsiro, Orsiro Mission, proBIO and BIOlute are trademarks or registered trademarks of the BIOTRONIK Group of Companies. Synergy, Synergy XD, Promus and Taxus are trademarks or registered trademarks of the Boston Scientific Group of Companies. Resolute, Integrity, Resolute Onyx and Resolute Integrity are trademarks or registered trademarks of the Medtronic Group of Companies. Xience and Xience Skypoint are trademarks or registered trademarks of the Abbott Group of Companies. Biofreedom and BioMatrix are trademarks or registered trademarks of the Biosensors International Group. Cre8 is a trademark or registered trademark of the Alvimedica Group of Companies. Nobori is a trademark or registered trademark of the Terumo Group of Companies. Cypher is a trademark or registered trademark of the Cardinal Health Group of Companies. 

© 2024 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.